ARWR vs REGN: Which Stock is Better?
Side-by-side comparison of Arrowhead Pharmaceuticals Inc and Regeneron Pharmaceuticals Inc in 2026
ARWR
Arrowhead Pharmaceuticals Inc
$70.53
REGN
Regeneron Pharmaceuticals Inc
$686.36
Key Metrics Comparison
| Metric | ARWR | REGN | Winner |
|---|---|---|---|
| Market Cap | $9.82B | $76.72B | REGN |
| P/E Ratio | 43.83 | 17.64 | REGN |
| EPS (TTM) | $1.60 | $41.49 | REGN |
| Revenue Growth | 104.6% | 0.0% | ARWR |
| Gross Margin | 100.0% | 44.6% | ARWR |
Analyze ARWR
Full quant analysis
Analyze REGN
Full quant analysis
Analyze Each Stock
Frequently Asked Questions
Is ARWR or REGN a better investment?
Comparing ARWR and REGN: Arrowhead Pharmaceuticals Inc has a market cap of $9.82B while Regeneron Pharmaceuticals Inc has $76.72B. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.
What is the difference between ARWR and REGN?
ARWR (Arrowhead Pharmaceuticals Inc) and REGN (Regeneron Pharmaceuticals Inc) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.
Which stock has better value: ARWR or REGN?
Based on P/E ratios, REGN trades at a lower multiple (17.6x vs 43.8x).
Which is growing faster: ARWR or REGN?
ARWR has higher revenue growth at 104.6% vs 0.0% for REGN.
Which company is more profitable: ARWR or REGN?
Arrowhead Pharmaceuticals Inc (ARWR) has higher gross margins at 100.0% compared to 44.6% for REGN.
Which is the larger company: ARWR or REGN?
Regeneron Pharmaceuticals Inc (REGN) is larger with a market cap of $76.72B compared to $9.82B for ARWR.
Should I buy ARWR or REGN in 2026?
Both ARWR and REGN have investment merit. ARWR trades at $70.53 while REGN trades at $686.36. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.
What are the key differences between ARWR and REGN stock?
Key differences: Market Cap ($9.82B vs $76.72B), P/E Ratio (43.8x vs 17.6x), Revenue Growth (104.6% vs 0.0%), Gross Margin (100.0% vs 44.6%).